Biogen Inc. 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-16 6:40 pm Sale | 2024-08-14 | 13G | Sangamo Therapeutics, Inc. SGMO | BIOGEN INC. BIIB | 3,250,000 1.600% | -11,402,466 (-77.82%) | Filing |
| 2024-02-12 7:11 pm Sale | 2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BIOGEN INC. BIIB | 14,652,466 8.260% | -9,767,691 (-40.00%) | Filing |